Navigation Links
Researchers publish molecular disease model for melanoma
Date:3/30/2011

ed therapy with potential efficacy for that subtype.

Commented Dr. Keith Flaherty, Director of Developmental Therapeutics at Massachusetts General Hospital and co-chief editor of Cancer Commons Melanoma: "While earlier stages of melanoma can be successfully treated by surgical excision, advanced stages are uniquely refractory to standard chemotherapy. Recent developments in our understanding of the molecular drivers of this disease have led to a new generation of targeted therapies that are proving effective in patients whose tumors harbor certain genetic defects. Rather than treating melanoma as a single disease, it makes sense to stratify tumors into molecular subtypes and treat each with the most appropriate therapies."

The molecular disease model for melanoma is the first of many such models planned by Cancer Commons, the open science initiative for personalized oncology that was initially convened by CollabRx. Cancer Commons is creating a network of rapid learning communities where physicians, scientists, and patients collaborate to provide each patient with the best possible outcome by personalizing therapy based on the tumor's genomic subtype. CollabRx is developing web-based applications and services that facilitate this collaboration; the first of these, The Targeted Therapy Finder Melanoma, leverages the MDMM to find treatments targeted to a patient's specific molecular profile.

"Cancer Commons puts the patient at the front end of a remarkable experiment in 'translational medicine' - one in which basic molecular biology, computational methods and a network of experts and institutions collaborate to work out personalized medical solutions," said Donald Kennedy, Ph.D., Editor-in-Chief, Science (2000-2008). "Our goal is to run this translational loop in real time, so that what is learned from one patient can be disseminated in time to help the next. By having researchers, clinicians and patients on the same platform, we can take y
'/>"/>

Contact: Jen Laloup
jlaloup@plos.org
415-624-1220
Public Library of Science
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. Researchers find possible clues to tamoxifen resistance in breast cancer patients
2. UCSF researchers identify promising new treatment for childhood leukemia
3. Researchers make the leap to whole-cell simulations
4. Stepchildren relate to stepparents based on perceived benefits, researchers find
5. Researchers find many elderly men are undergoing unnecessary PSA screenings
6. AACR and Landon Foundation support the next generation of researchers with INNOVATOR Awards
7. Can you hear me now? Researchers detail how neurons decide how to transmit information
8. AACR honors eminent researchers
9. Penn researchers uncover novel immune therapy for pancreatic cancer
10. Researchers: Sexually active teens need confidential health care
11. Researchers develop a halometer that tests alterations in night vision
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/21/2014)... 21, 2014 Originally approved by ... GSK’s Flovent (fluticasone propionate) is a synthetic ICS ... for the maintenance treatment of asthma prophylactically in ... two formulations, Diskus and HFA, which received the ... active ingredient, fluticasone propionate, can bind to glucocorticoid ...
(Date:9/21/2014)... An experienced review website in the global ... list and announced that FatCow ( http://www.top10bestseohosting.com/go/FatCow.com/ ), GoDaddy ... , There has been a boom in websites in ... an increase in the number of web hosting companies ... affordable prices. VPS (Virtual Private Server) is the method ...
(Date:9/21/2014)... OH (PRWEB) September 21, 2014 C8 ... District of Ohio as the list of 20 possible ... been narrowed down to six, reports Wright & Schulte ... chosen from the almost 2500 C8 lawsuits filed that ... or testicular cancer as a result of being exposed ...
(Date:9/20/2014)... Vegas, NV (PRWEB) September 21, 2014 ... by Dr. Kenneth Pullman that is helping thousands of ... their diabetes symptoms without shots, pills, or prescriptions has ... review. , “There are currently tens of millions ... both Type 1 and Type 2 diabetes, and unfortunately, ...
(Date:9/20/2014)... Baja, Mexico (PRWEB) September 20, 2014 ... announced the resort did not experience any damage in ... all amenities and activities available. , Hurricane Odile struck ... bringing intense wind, rain and powerful surf conditions. Located ... del Palmar Islands of Loreto experienced some heavy rain, ...
Breaking Medicine News(10 mins):Health News:Flovent Asthma Market Sales & SWOT Analysis and Forecasts to 2023 in New Report Available at LifeScienceIndustryResearch.com 2Health News:Flovent Asthma Market Sales & SWOT Analysis and Forecasts to 2023 in New Report Available at LifeScienceIndustryResearch.com 3Health News:Flovent Asthma Market Sales & SWOT Analysis and Forecasts to 2023 in New Report Available at LifeScienceIndustryResearch.com 4Health News:Top10BestSEOHosting.com: FatCow, GoDaddy And Bluehost Are The Best VPS Hosting Suppliers 2Health News:C8 Lawsuit Claims Move Forward as Six Possible Cases for Bellwether Trials Selected in DuPont Water Contamination Lawsuits, Reports Wright & Schulte LLC 2Health News:C8 Lawsuit Claims Move Forward as Six Possible Cases for Bellwether Trials Selected in DuPont Water Contamination Lawsuits, Reports Wright & Schulte LLC 3Health News:C8 Lawsuit Claims Move Forward as Six Possible Cases for Bellwether Trials Selected in DuPont Water Contamination Lawsuits, Reports Wright & Schulte LLC 4Health News:Diabetes Protocol: Review Exposes Kenneth Pullman’s Breakthrough Discovery About Diabetes Management 2Health News:Villa del Palmar at the Islands of Loreto Fully Functioning After Hurricane 2Health News:Villa del Palmar at the Islands of Loreto Fully Functioning After Hurricane 3
... , , , ... JAZZ ) today announced financial results for the second quarter ended June ... quarter were $37.3 million, compared to $15.5 million for the quarter ended ... milestone payment from UCB Pharma Limited that was received in July 2008 ...
... , LAKEWOOD, Colo., Aug. 11 Mesa Laboratories, ... of Directors has declared a regular quarterly cash dividend of 10 ... to shareholders of record at the close of business on August ... manufactures and markets electronic instruments and disposables for industrial, pharmaceutical and ...
... VERNON HILLS, Ill., Aug. 11 Lifeline Vascular Access(SM), the ... the launch of the Lifeline Vascular Access Network(SM) - ... to deliver quality care and impact industry-wide health-care cost savings. ... money for end-stage renal disease (ESRD) patients and the entire ...
... , , , ... a worldwide manufacturer and distributor of agricultural equipment, today ... Norman L. Boyd, has been appointed by Governor Perdue ... of Community Health champions access to affordable, quality health ...
... , New Studies Show Healthy Lifestyle Habits ... WASHINGTON, Aug. 11 Though years ago everyone was looking for ... of chronic disease, scientific researchers today recognize that it is the ... a healthy diet, using dietary supplements and exercising regularly -- that ...
... who ate healthy and remained active were protected, study ... a Mediterranean diet, which emphasizes fruits, vegetables, legumes and ... the risk of developing Alzheimer,s disease, a new study ... 12 issue of the Journal of the American ...
Cached Medicine News:Health News:Jazz Pharmaceuticals Announces Second Quarter 2009 Financial Results 2Health News:Jazz Pharmaceuticals Announces Second Quarter 2009 Financial Results 3Health News:Jazz Pharmaceuticals Announces Second Quarter 2009 Financial Results 4Health News:Jazz Pharmaceuticals Announces Second Quarter 2009 Financial Results 5Health News:Jazz Pharmaceuticals Announces Second Quarter 2009 Financial Results 6Health News:Jazz Pharmaceuticals Announces Second Quarter 2009 Financial Results 7Health News:Jazz Pharmaceuticals Announces Second Quarter 2009 Financial Results 8Health News:Lifeline Vascular Access Launches New Platform for Physicians to Share Best Practices and Improve Vascular Access Care 2Health News:AGCO Senior Executive, Norm Boyd, Receives Executive Appointment to Georgia's Board of Community Health by Georgia Governor Sonny Perdue 2Health News:Healthy Lifestyles Are 'In' - Magic Bullets Are 'Out' 2Health News:Healthy Lifestyles Are 'In' - Magic Bullets Are 'Out' 3Health News:Healthy Lifestyles Are 'In' - Magic Bullets Are 'Out' 4Health News:Mediterranean Diet Plus Exercise Lowers Alzheimer's Risk 2Health News:Mediterranean Diet Plus Exercise Lowers Alzheimer's Risk 3
(Date:9/19/2014)... , September 19, 2014 ... ) has announced the addition of the ... report to their offering.      ... have been broadly classified into wide categories ... used for the treatment of different gynecological ...
(Date:9/19/2014)... Sept. 19, 2014  For Cloud Pharmaceuticals, Inc., ... and development, partnering is an integral part of ... design new drugs and identify early stage, preclinical, ... further their development. The company also partners with ... this business model, Cloud Pharmaceuticals will be participating ...
(Date:9/19/2014)... The American Association for Homecare (AAHomecare) is ... has joined the AAHomecare Corporate Partner Program. ... have been actively involved in AAHomecare for much of ... grown into a major global manufacturer of home medical ... to increase efforts on behalf of the HME sector ...
Breaking Medicine Technology:Global Gynecological Devices Market 2014-2018: Key Vendors are Bayer, Boston Scientific, CooperSurgical, Ethicon, Hologic, Medtronic, Olympus and Stryker 2Global Gynecological Devices Market 2014-2018: Key Vendors are Bayer, Boston Scientific, CooperSurgical, Ethicon, Hologic, Medtronic, Olympus and Stryker 3Cloud Pharmaceuticals Announces Partnering Sessions and Presentation Schedule 2Drive Medical Design & Manufacturing Joins AAHomecare Corporate Partner Program 2
... CAMBRIDGE, Mass. , Aug. 4 ... therapies to treat autoimmune diseases and cancer by modulating ... Antonin (Tony) de Fougerolles , Ph.D., as Chief Scientific ... provide leadership for the company’s research and early-stage product ...
... , THE WOODLANDS, Texas , Aug. 3 ... LXRX ), a biopharmaceutical company focused on discovering breakthrough ... its second quarter 2010 financial results on Monday, August ... will hold a conference call to discuss its clinical development ...
Cached Medicine Technology:Tolerx Appoints Antonin de Fougerolles, Ph.D., as Chief Scientific Officer 2Tolerx Appoints Antonin de Fougerolles, Ph.D., as Chief Scientific Officer 3Tolerx Appoints Antonin de Fougerolles, Ph.D., as Chief Scientific Officer 4Lexicon to Provide Clinical Pipeline Update and Report Second Quarter 2010 Financial Results 2
... Electronic Medical Record system. It stores patient chart ... and everything you would normally put in a ... Someone has to write them, file them, find ... Paper Charts get lost. They find their way ...
... precision demands absolute knowledge. Access ... Lomb Zyoptix Diagnostic Workstation, uniting ... Wavefront Aberrometer and Orbscan IIz ... they supply critically important data. ...
ZYMAR™ ophthalmic solution is an anti-infective prescription eye drop that your doctor may instruct you to use if you have an eye infection caused by bacteria. Bacterial conjunctivitis is the e...
LUMIGAN® is a powerful eye drop medication for lowering IOP. IOP is short for intraocular pressure or eye pressure. LUMIGAN® is the first in a new class of medication....
Medicine Products: